BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics

We love to hear from our listeners. Send us a message. (buzzsprout.com/1011661/fan_mail/new)
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian talks about why he selected BPD as a lead clinical indication (a disease primarily affecting preterm infants), what he learned through founding and selling a CRO, how a private biotech funds a pivotal trial across continents, and offers an industry outlook for 2026.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (lifescienceleader.com/solution/the-business-of…) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (www9.lifescienceleader.com/business-of-biotech…).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: linkedin.com/in/bencomer